ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eculizumab

Also written as “Eculizumab”, “Eculizumab Injection” and “Soliris (eculizumab)”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Myasthenia Gravis · Neuromyelitis Optica · Guillain-Barre Syndrome, led by 4 companies.

Drug pageEculizumab: every studyAll 81 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 23, 200936 company-led studies, 1 open or runningNext primary completion: Dec 7, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only311 open or runningphase 4since Mar 23, 2009Jul 18, 2005Dec 7, 2026phase 3 · NCT06724809
AO GENERIUMits history only20 open or runningphase 3since Jul 3, 2020Jul 3, 2020none ahead
Samsung Bioepisits history only20 open or runningphase 3since Aug 12, 2019Oct 24, 2018none ahead
Biocad10 open or runningphase 3since May 16, 2025May 16, 2025none ahead

Also a collaborator on its studies: CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biocad only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2025First study: phase 3 study in Hemoglobinuria, ParoxysmalFirst studyNCT06987864 · 24 enrolled · Russian Federation

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

The one study Biocad leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06987864Hemoglobinuria, Paroxysmal · Russian Federation3CompletedNov 2, 202224

How it is read

Names in the registry

  • “Eculizumab”, 23 entries
  • “eculizumab”, 10 entries
  • “Eculizumab Injection”, 1 entry
  • “Soliris (eculizumab)”, 1 entry
  • “Elizaria®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.